دورية أكاديمية
أعرض في EDS

STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells.

التفاصيل البيبلوغرافية
العنوان: STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells.
المؤلفون: Wang L; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Liang Z; Bioland Laboratory (Guangzhou Regenerative Medicine and Health GuangDong Laboratory), Guangzhou, 510005, China., Guo Y; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Habimana JD; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Ren Y; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Amissah OB; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Mukama O; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.; Department of Biology, College of Science and Technology, University of Rwanda, Kigali, 3900, Rwanda., Peng S; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China., Ding X; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Lv L; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Li J; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Chen M; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Liu Z; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Huang R; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China., Zhang Y; Department of Breast Surgery, Second Hospital of Jilin University, Changchun, 130022, China., Li Y; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China. li_yi@gibh.ac.cn., Li Z; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China. li_zhiyuan@gibh.ac.cn.; GZMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, 510530, China. li_zhiyuan@gibh.ac.cn., Sun Y; CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China. sun_yirong@gibh.ac.cn.
المصدر: Cell death & disease [Cell Death Dis] 2024 Apr 13; Vol. 15 (4), pp. 265. Date of Electronic Publication: 2024 Apr 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Pub. Group
مواضيع طبية MeSH: T-Lymphocytes* , Neoplasms*/therapy, Antigen Presentation ; Antibodies ; Flow Cytometry ; Receptors, Antigen, T-Cell
مستخلص: Antigen-specific T cell receptor-engineered T cell (TCR-T) based immunotherapy has proven to be an effective method to combat cancer. In recent years, cross-talk between the innate and adaptive immune systems may be requisite to optimize sustained antigen-specific immunity, and the stimulator of interferon genes (STING) is a promising therapeutic target for cancer immunotherapy. The level of expression or presentation of antigen in tumor cells affects the recognition and killing of tumor cells by TCR-T. This study aimed at investigating the potential of innate immune stimulation of T cells and engineered T cells to enhance immunotherapy for low-expression antigen cancer cells. We systematically investigated the function and mechanism of cross-talk between STING agonist diABZI and adaptive immune systems. We established NY-ESO-1 full knockout Mel526 cells for this research and found that diABZI activated STING media and TCR signaling pathways. In addition, the results of flow cytometry showed that antigens presentation from cancer cells induced by STING agonist diABZI also improved the affinity of TCR-T cells function against tumor cells in vitro and in vivo. Our findings revealed that diABZI enhanced the immunotherapy efficacy of TCR-T by activating STING media and TCR signaling pathways, improving interferon-γ expression, and increasing antigens presentation of tumor cells. This indicates that STING agonist could be used as a strategy to promote TCR-T cancer immunotherapy.
(© 2024. The Author(s).)
References: J Exp Med. 2021 Feb 1;218(2):. (PMID: 33382402)
J Cell Physiol. 2019 Jun;234(6):8509-8521. (PMID: 30520029)
Front Immunol. 2022 Mar 03;13:835762. (PMID: 35309357)
Immunity. 2014 Nov 20;41(5):830-42. (PMID: 25517615)
Nat Immunol. 2016 Sep 20;17(10):1142-9. (PMID: 27648547)
Nat Rev Immunol. 2020 Nov;20(11):651-668. (PMID: 32433532)
Lancet Oncol. 2020 Mar;21(3):e168-e178. (PMID: 32135120)
Front Immunol. 2022 Jan 03;12:795401. (PMID: 35046953)
Cell Death Dis. 2019 Feb 21;10(3):177. (PMID: 30792387)
Cancers (Basel). 2021 May 30;13(11):. (PMID: 34070756)
Nat Commun. 2023 Mar 23;14(1):1610. (PMID: 36959214)
Cells. 2022 Mar 29;11(7):. (PMID: 35406723)
Nat Biotechnol. 2005 Mar;23(3):349-54. (PMID: 15723046)
Mol Cancer Ther. 2021 Nov;20(11):2302-2313. (PMID: 34465596)
Immunity. 2019 Apr 16;50(4):1007-1023. (PMID: 30995492)
Nat Med. 2012 Aug;18(8):1224-31. (PMID: 22820642)
Immunology. 2022 Jun;166(2):210-221. (PMID: 35298836)
J Immunol Res. 2017;2017:3145742. (PMID: 28265580)
Nat Commun. 2018 Jul 17;9(1):2770. (PMID: 30018345)
Curr Microbiol. 2022 Jan 29;79(3):77. (PMID: 35091848)
Mol Cancer. 2020 Sep 4;19(1):136. (PMID: 32887628)
Nat Rev Immunol. 2021 Sep;21(9):548-569. (PMID: 33833439)
Genes (Basel). 2020 Aug 25;11(9):. (PMID: 32854287)
PLoS One. 2019 Aug 8;14(8):e0219829. (PMID: 31393905)
Cell Death Dis. 2016 Aug 18;7(8):e2342. (PMID: 27537525)
Nature. 2020 Oct;586(7829):429-433. (PMID: 32877915)
Nat Med. 2015 Aug;21(8):914-921. (PMID: 26193344)
J Exp Med. 2022 Feb 7;219(2):. (PMID: 34935874)
Nat Rev Immunol. 2015 Dec;15(12):760-70. (PMID: 26603901)
Nat Rev Immunol. 2015 Jul;15(7):405-14. (PMID: 26027717)
Eur J Immunol. 2020 Oct;50(10):1580-1590. (PMID: 32441316)
Immunity. 2010 Feb 26;32(2):163-74. (PMID: 20137987)
Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2214331119. (PMID: 36442096)
Nat Commun. 2021 Sep 6;12(1):5303. (PMID: 34489451)
Immunotherapy. 2009 Nov;1(6):949-64. (PMID: 20563267)
Mol Cancer. 2019 Nov 4;18(1):152. (PMID: 31679519)
J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33323464)
Cancer Immunol Immunother. 2013 Apr;62(4):773-85. (PMID: 23263452)
Nature. 2009 Oct 8;461(7265):788-92. (PMID: 19776740)
Mol Cancer. 2018 Nov 17;17(1):158. (PMID: 30447690)
J Immunol. 2000 Oct 1;165(7):3571-7. (PMID: 11034357)
J Hematol Oncol. 2023 Feb 8;16(1):8. (PMID: 36755342)
J Exp Clin Cancer Res. 2021 Aug 11;40(1):253. (PMID: 34380537)
معلومات مُعتمدة: TSBICIP-KJGG -011 Tianjin Science and Technology Committee (Tianjin Municipal Science and Technology Commission); 202102080376 Guangzhou Science, Technology and Innovation Commission (Bureau of Science and Information Technology of Guangzhou Municipality); 202102020328 Guangzhou Science, Technology and Innovation Commission (Bureau of Science and Information Technology of Guangzhou Municipality)
المشرفين على المادة: 0 (Antibodies)
0 (Receptors, Antigen, T-Cell)
تواريخ الأحداث: Date Created: 20240413 Date Completed: 20240415 Latest Revision: 20240416
رمز التحديث: 20240416
مُعرف محوري في PubMed: PMC11016101
DOI: 10.1038/s41419-024-06638-1
PMID: 38615022
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-4889
DOI:10.1038/s41419-024-06638-1